MiNK Therapeutics officer reports 222-share Form 3 holding

MiNK Therapeutics, Inc. Principal Financial Officer Melissa Orilall filed an initial Form 3 showing an existing indirect holding of common stock.

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. Principal Financial Officer Melissa Orilall filed an initial Form 3 showing an existing indirect holding of common stock. The filing reports beneficial ownership of 222 shares held indirectly through her spouse, with no new buy or sell transaction disclosed.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Orilall Melissa

Role Principal Financial Officer

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 222 shares (Indirect, By spouse)

Key Figures

Indirect common shares: 222 shares Reported buy transactions: 0 transactions Reported sell transactions: 0 transactions

3 metrics

Indirect common shares 222 shares Indirectly owned by spouse as reported on Form 3

Reported buy transactions 0 transactions Form 3 transaction summary buyCount

Reported sell transactions 0 transactions Form 3 transaction summary sellCount

Key Terms

Form 3, Principal Financial Officer, indirect ownership, beneficial ownership

4 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Principal Financial Officer financial

""officer_title": "Principal Financial Officer""

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

indirect ownership financial

""ownership_type": "indirect""

beneficial ownership financial

"The filing reports beneficial ownership of 222 shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the MiNK Therapeutics (INKT) Form 3 filing show for Melissa Orilall?

The Form 3 shows Melissa Orilall, Principal Financial Officer, reporting indirect beneficial ownership of 222 shares of MiNK Therapeutics common stock. These shares are held by her spouse, reflecting an existing position rather than a new transaction.

Did Melissa Orilall buy or sell MiNK Therapeutics (INKT) shares in this Form 3?

No. The Form 3 is an initial ownership report and does not show any buy or sell transaction. It simply discloses an indirect holding of 222 common shares attributed to her spouse as of the reported date.

How are the 222 MiNK Therapeutics (INKT) shares held for Melissa Orilall?

The 222 shares of MiNK Therapeutics common stock are reported as held indirectly “by spouse”. This means the position is attributed to Melissa Orilall through her spouse’s holdings, rather than being directly in her own name.

What role does Melissa Orilall hold at MiNK Therapeutics (INKT) in this Form 3?

In this Form 3, Melissa Orilall is identified as an officer of MiNK Therapeutics, serving as the Principal Financial Officer. The filing links her corporate role to the disclosed indirect ownership of common stock.

Does the MiNK Therapeutics (INKT) Form 3 indicate any derivative securities for Melissa Orilall?

No derivative securities are listed for Melissa Orilall in this Form 3. The filing’s holdings disclosure focuses solely on 222 indirectly owned common shares, with no options, warrants, or other derivative positions shown in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Orilall Melissa

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/13/2026

3. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	222	I	By spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Melissa Orilall	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)